Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Alvarez

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Translational Psychiatry|November 1, 2025
Invasive brain mapping identifies personalized therapeutic neuromodulation targets that suppress OCD network activityA Moses Lee, Audrey Kist, John Alvarez, et al.
Medrxiv : the Preprint Server for Health Sciences|June 5, 2026
Targeted Connectomic Neuromodulation of the Orbitofrontal Cortex To Treat Obsessive-Compulsive DisorderEmma Anderson, Audrey Kist, Zachary D Simon, et al.
The Lancet. Haematology|January 16, 2019
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a studyAnas Younes, Joshua Brody, Cecilia Carpio, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Translational Psychiatry|November 1, 2025
Invasive brain mapping identifies personalized therapeutic neuromodulation targets that suppress OCD network activityA Moses Lee, Audrey Kist, John Alvarez, et al.
Medrxiv : the Preprint Server for Health Sciences|June 5, 2026
Targeted Connectomic Neuromodulation of the Orbitofrontal Cortex To Treat Obsessive-Compulsive DisorderEmma Anderson, Audrey Kist, Zachary D Simon, et al.
The Lancet. Haematology|January 16, 2019
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a studyAnas Younes, Joshua Brody, Cecilia Carpio, et al.
Pageof 3